Related Experiment Video
Updated: Oct 1, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Pancytopenia in a patient treated with fusidic acid and niraparib: a case report
Margaux Damerval1, Fernando Bazan2, Selim Omrani3
1Territoire de Belfort, Hopital Nord Franche-Comte - Site de Belfort, Trévenans, Franche-Comté, France margaux.damerval@orange.fr.
Abstract:
Fusidic acid is an antibiotic used in the treatment of staphylococcal infections. Niraparib is an anticancer drug indicated for the treatment of advanced ovarian cancer. The interaction between these two drugs has not been studied and is not referenced in drug databases. We present the case of a patient with pancytopenia who had been treated with fusidic acid and niraparib. No other treatment was taken by this patient. According to the literature, both substances can cause haematological toxicity. It seems unlikely that this is due to niraparib alone because it had been well tolerated by the patient for over a year before the pancytopenia was diagnosed. It was also perfectly well tolerated when it was reintroduced. We cannot determine whether this pancytopenia is due to fusidic acid alone or to a drug interaction between the two treatments. We therefore recommend caution in patients treated with this combination.
Related Concept Videos
Treatment Resistant Cancers
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

